PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1913432
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1913432
Assisted Reproductive Technology (ART) Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026 - 2035
The Global Assisted Reproductive Technology (ART) Market was valued at USD 38.9 billion in 2025 and is estimated to grow at a CAGR of 7.6% to reach USD 79.8 billion by 2035.
The market expansion is fueled by continuous technological advancements that enhance treatment effectiveness and patient experience. Innovations such as AI-driven embryo selection, time-lapse imaging, and preimplantation genetic testing (PGT) are improving implantation outcomes while reducing cycle failures, making ART increasingly reliable and appealing. Assisted reproductive technology encompasses medical procedures designed to help individuals or couples conceive when natural conception is challenging, involving the manipulation of eggs, sperm, or embryos outside the body. Changing social norms and greater acceptance of diverse family structures, including single-parent and same-sex families, have broadened the demand for ART solutions. Rising awareness, evolving parental expectations, and growing acceptance of reproductive alternatives have collectively accelerated market growth, creating opportunities for clinics, technology providers, and ancillary service providers globally.
| Market Scope | |
|---|---|
| Start Year | 2025 |
| Forecast Year | 2026-2035 |
| Start Value | $38.9 Billion |
| Forecast Value | $79.8 Billion |
| CAGR | 7.6% |
The technology segment reached USD 31.2 billion in 2025, reflecting high demand for advanced reproductive solutions driven by lifestyle changes, environmental factors, and delayed parenthood.
The fertility clinics segment generated USD 17.6 billion in 2025, dominating the service landscape as specialized centers employing reproductive endocrinologists, embryologists, and fertility experts to deliver high success rates.
North America Assisted Reproductive Technology (ART) Market remains the largest regional market, supported by a robust healthcare infrastructure, high patient awareness, strong regulatory frameworks, and widespread adoption of innovative technologies such as AI-based embryo selection, genetic screening, and cryopreservation techniques. Rising infertility prevalence and government or insurance initiatives to reduce financial barriers further strengthen market adoption.
Prominent players in the Global Assisted Reproductive Technology (ART) Market include Hamilton Thorne, Western Fertility Institute, Kitazato, Indira IVF Hospital, Gynotec, Merck, Esco Micro, Ivy Fertility, Laboratoire, Liverpool Partners Group, Thermo Fisher Scientific, The Cooper Companies, Vitrolife Group, NidaCon International, and Mistral Fertility Clinics. Companies in the Global Assisted Reproductive Technology (ART) Market are reinforcing their position through investment in research and development to enhance treatment success rates and patient outcomes. Strategic partnerships with fertility clinics, hospitals, and diagnostic labs help expand service networks and improve accessibility. Adoption of AI, genetic testing, and cryopreservation innovations enables differentiation through advanced and efficient treatment solutions. Firms are also focusing on geographic expansion into high-demand regions and providing patient education programs to build trust and awareness.
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market scope and definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
- 2.2 Key market trends
- 2.2.1 Regional trends
- 2.2.2 Product trends
- 2.2.3 Procedures trends
- 2.2.4 End use trends
- 2.3 CXO perspectives: Strategic imperatives
- 2.3.1 Key decision points for industry executives
- 2.3.2 Critical success factors for market players
- 2.4 Future outlook and strategic recommendations
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Rising prevalence of infertility across population base
- 3.2.1.2 Demographical shift towards acceptance of assisted reproductive technology (ART)
- 3.2.1.3 Technological advancements in assisted reproductive technology
- 3.2.1.4 Rising awareness regarding assisted reproductive technology
- 3.2.2 Industry pitfalls and challenges
- 3.2.2.1 Stringent regulatory scenario
- 3.2.2.2 High cost of ART procedures
- 3.2.3 Market opportunity
- 3.2.3.1 Personalized and precision reproductive medicine
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.4.1 North America
- 3.4.2 Europe
- 3.4.3 Asia Pacific
- 3.5 Technological landscape
- 3.6 Future market trends
- 3.7 Porter's analysis
- 3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2024
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.2.1 Global
- 4.2.2 North America
- 4.2.3 Europe
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Key developments
- 4.6.1 Merger and acquisition
- 4.6.2 Partnership and collaboration
- 4.6.3 New product launches
- 4.6.4 Expansion plans
Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)
- 5.1 Key trends
- 5.2 Media
- 5.2.1 Embryo culture media
- 5.2.2 Cryopreservation media
- 5.2.3 Semen processing media
- 5.2.4 Ovum processing media
- 5.3 Instrument
- 5.3.1 Vitrification devices
- 5.3.2 Incubators
- 5.3.3 Sperm analyzer system
- 5.3.4 Micromanipulators
- 5.3.5 Other instruments
- 5.4 Consumables
- 5.4.1 Catheters
- 5.4.2 Needles
- 5.4.3 Storage containers
- 5.4.4 Other consumables
- 5.5 Supplements
Chapter 6 Market Estimates and Forecast, By Procedure, 2021 - 2034 ($ Mn)
- 6.1 Key trends
- 6.2 Technology
- 6.2.1 In-vitro fertilization (IVF)
- 6.2.1.1 IVF with intracytoplasmic sperm injection (ICSI)
- 6.2.1.2 IVF without ICSI
- 6.2.2 Artificial insemination - intrauterine insemination (AI-IUI)
- 6.2.1 In-vitro fertilization (IVF)
- 6.3 Type
- 6.3.1 Fresh donor
- 6.3.2 Fresh non donor
- 6.3.3 Frozen donor
- 6.3.4 Frozen non donor
Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)
- 7.1 Key trends
- 7.2 Hospitals
- 7.3 Fertility clinics
- 7.4 Cryobanks
- 7.5 Other end use
Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)
- 8.1 Key trends
- 8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
Chapter 9 Company Profiles
- 9.1 Esco Micro
- 9.2 Gynotec
- 9.3 Hamilton Thorne
- 9.4 Indira IVF Hospital
- 9.5 Ivy Fertility
- 9.6 Kitazato
- 9.7 Laboratoire
- 9.8 Liverpool Partners Group
- 9.9 Merck
- 9.10 MISTRAL FERTILITY CLINICS
- 9.11 NidaCon International
- 9.12 The Cooper Companies
- 9.13 Thermo Fisher Scientific
- 9.14 Vitrolife Group
- 9.15 Western Fertility Institute
